#weight-loss

As of 2026, two FDA-approved oral GLP-1 pills exist for weight loss: Foundayo (orforglipron, 12.4% weight loss, $149/mo self-pay via LillyDirect, no fasting needed, approved April 1) and the Wegovy pill (semaglutide 25mg, 16.6% weight loss, $1,349/mo list price, requires 30-min fast before dosing, approved December 2025). Rybelsus is oral semaglutide but approved for type 2 diabetes only — not weight loss.

Updated May 18, 2026 with Week 5 IQVIA data: 10,248 weekly Rx (+40% week-over-week re-acceleration). Oral Wegovy produces 16.6% body weight loss vs Foundayo's 12.4%, but Foundayo starts at $149/mo self-pay (WAC $649/mo) vs Wegovy's $1,349/mo and has no fasting requirement. PBM formulary activation expected to drive Week 6 acceleration. Full comparison with OASIS and ATTAIN trial data.

Verified May 2026: Tirzepatide starts at 2.5 mg once weekly (non-therapeutic starter dose), escalates by 2.5 mg every 4 weeks to a maximum of 15 mg once weekly. Full escalation takes 20 weeks. At 72 weeks, the 15 mg dose produced 20.9% body weight loss in SURMOUNT-1 — equivalent to roughly 47 lbs for a 225-lb person. The 5 mg and 10 mg doses are also valid long-term maintenance doses (15% and 19.5% weight loss respectively). Same dosing schedule applies to Zepbound, Mounjaro, and compounded tirzepatide.

Updated May 2026: 5 next-gen obesity drugs in Phase 3. Retatrutide (Lilly) 28.7% weight loss. CagriSema (Novo): REDEFINE-1 22.7% (obesity), REDEFINE-2 15.7% (T2D), PDUFA expected October 2026. MariTide (Amgen, monthly), survodutide, Foundayo approved April 2026. FDA approvals 2026-2028.

Updated April 29, 2026: Foundayo (orforglipron) is the first non-peptide GLP-1 pill for weight loss, FDA-approved April 1, 2026. Produces 12.4% body weight loss over 72 weeks per ATTAIN-1 trial. ACHIEVE-4 (April 2026): 57% lower all-cause death vs insulin glargine (HR 0.43, 2,700 patients). Self-pay starts at $149/month (starting dose) via LillyDirect, $299/month at maintenance doses. No food or water restrictions — take any time.

Verified April 2026: Zepbound and Mounjaro are the exact same drug (tirzepatide) at the same doses. Mounjaro was FDA-approved May 2022 for Type 2 diabetes. Zepbound was FDA-approved November 2023 for chronic weight management and December 2024 for obstructive sleep apnea. List price is ~$1,087/mo for both; with commercial insurance + savings cards both drop to $25/mo (max $1,950/yr). The real differences: which one your insurance covers, what the FDA label allows, and Zepbound's LillyDirect self-pay vials at $299-$449/mo — a program Mounjaro does not offer.

Verified April 2026: Zepbound (tirzepatide) side effects from the SURMOUNT clinical trials — nausea affects 24-29% of patients (vs 8% placebo), diarrhea 19-23%, vomiting 8-13%. Only 4.3% discontinued at the highest dose. GI symptoms peak during dose escalation and resolve within 4-8 weeks for most patients. Full breakdown by dose, timeline, management strategies, and when to call your doctor.

How much do GLP-1 medications cost in 2026? Wegovy, Zepbound, Ozempic, Mounjaro & Foundayo range from $25–$1,350/month. With insurance + savings card: $25/mo. Without insurance: $115/mo compounded sema (Enhance MD), $149/mo Foundayo pill, $299–449/mo brand injectable (LillyDirect, NovoCare). Medicare: $50/mo starting July 2026. Prices verified April 17, 2026 across 48 providers.

Medicare will begin covering GLP-1 weight loss medications at $50/month starting July 2026. Here's who qualifies, how it works, and what comes next.

FDA-approved GLP-1 receptor agonists for weight loss — 2026 guide. Eligibility: BMI 30+ (or 27+ with comorbidity). Semaglutide produces 14.9% weight loss (STEP-1), tirzepatide 20.9% (SURMOUNT-1). Cost: $25-$349/mo via telehealth. Complete 5-step prescription process with verified provider pricing. Options: Foundayo (orforglipron), oral Wegovy, Zepbound, and injectable semaglutide.

Verified April 2026: Brand-name Wegovy is $349/mo via NovoCare, Zepbound starts at $299/mo via LillyDirect. Compounded semaglutide is banned since Feb 2025; compounded tirzepatide remains legal at $149-299/mo under narrow medical-necessity rules. Full legal + safety comparison.

Verified April 2026: GLP-1 patients lose 2-5 pounds in their first month. Appetite suppression starts week 1-2. Nausea peaks at week 4 dose escalation. 98.1% of GI side effects are mild-to-moderate per STEP-1 and SURMOUNT-1 trials. Complete week-by-week timeline with dosing schedule.

Verified April 2026: Retatrutide (Eli Lilly, LY-3437943) achieved 28.7% body weight loss in Phase 3 TRIUMPH trials — nearly double semaglutide (14.9%) and 37% higher than tirzepatide (20.9%). First triple-agonist (GLP-1 + GIP + glucagon). FDA approval expected late 2027 to early 2028.

Verified April 2026: Medicare Part D begins covering Wegovy and Zepbound for weight loss July 1, 2026 via the Medicare GLP-1 Bridge program. Flat $50/month copay. 3.4 million beneficiaries eligible. Runs through Dec 31, 2026, then permanent BALANCE Model launches January 2027.

Verified April 2026: Ozempic and Wegovy are both semaglutide from Novo Nordisk. Ozempic ($1,028/mo list) is approved for type 2 diabetes at max 2mg. Wegovy ($1,349/mo list) is approved for weight loss at max 2.4mg (or 7.2mg HD). Both drop to $349/mo self-pay via NovoCare.

Verified April 2026: Oral Wegovy (25mg daily pill) produces 16.6% weight loss per the OASIS trial vs 14.9% for injectable Wegovy (2.4mg weekly) per STEP-1. Pill costs $1,349/mo list vs $349/mo self-pay for the injection through NovoCare. Full head-to-head comparison.

Verified April 2026: Tirzepatide produces 20.2% weight loss vs semaglutide's 13.7% in the head-to-head SURMOUNT-5 trial (NEJM). Tirzepatide activates GLP-1 + GIP dual receptors; semaglutide activates GLP-1 only. Tirzepatide costs $449/mo vs $349/mo self-pay. Full comparison.

Verified April 2026: The 7 worst foods on Ozempic, Wegovy, Zepbound — fried food, sugary drinks, red meat portions, raw cruciferous veg, carbonated beverages, alcohol, high-fiber bars. GLP-1s slow gastric emptying 25-40%, triggering nausea in 44% of patients. Full list with alternatives.

Verified April 2026: 44% of Wegovy patients report nausea, 30% diarrhea, 24% vomiting in STEP-1 trial. Only 7% discontinued for side effects. Tirzepatide (Zepbound) is more tolerable: 24-33% nausea, 7-13% vomiting per SURMOUNT-1. Full management guide with red flags.

Verified April 11, 2026: Foundayo (orforglipron) shipped to LillyDirect patients starting April 6. First-week fill rate hit 94% within 48 hours of order. Pricing confirmed: $649/mo self-pay, $25/mo with commercial insurance + Lilly savings card. Here's exactly how to order today.

Clinical trials show 15–17% body weight loss with semaglutide over 68 weeks. Here's what to expect month by month, backed by data from the STEP trials.

GLP-1 patches sold online don't contain semaglutide or tirzepatide — they're herbal supplements. Here's what the science says and what actually works.

Two of the biggest telehealth platforms now offer branded Wegovy and GLP-1 programs. We compare Ro and Hims on pricing, medications, insurance, clinical support, and what actually changed after the Novo Nordisk lawsuit.

The FDA just approved Eli Lilly's Foundayo (orforglipron) — the only GLP-1 weight loss pill with no food, water, or timing restrictions. Here's what it costs, how it works, and how it compares to Wegovy and Zepbound.